((自动化翻译由路透提供，请见免责声明 ))
10月9日 - ** 抗糖尿病药物生产商Ocugen 股价上涨1.75%，报0.98美元
** 在美国食品和药物管理局解除临床搁置后，该公司的糖尿病黄斑水肿治疗药物$(DME.AU)$, OCU200 现在可以开始第一阶段临床试验了 (link)
** 糖尿病黄斑水肿是一种由于视网膜血管异常增生而导致糖尿病患者眼睛受损的疾病。
** 美国 FDA 于 2023 年 4 月要求公司在开始试验前提供有关生产实践和产品规格的更多信息
** 公司打算为该药物寻求更多适应症，以治疗糖尿病视网膜病变和湿性老年性黄斑变性。
** 截至周二收盘，公司股价已累计上涨 69.7
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.